Differential activation of extracellular signal-regulated protein kinase 1/2 and p38 mitogen activated-protein kinase by AT1 receptors in vascular smooth muscle cells from Wistar–Kyoto rats and spontaneously hypertensive rats
- 1 March 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 19 (3) , 553-559
- https://doi.org/10.1097/00004872-200103001-00006
Abstract
The present study investigates effects of angiotensin II on activation of extracellular signal-regulated protein kinase (ERK) 1/2, p38 mitogen activated-protein kinase (p38MAPK) and c-Jun amino terminal kinase (JNK) in vascular smooth muscle cells from spontaneously hypertensive rats (SHR). Vascular smooth muscle cells (VSMC) from mesenteric arteries of Wistar–Kyoto (WKY) rats and SHR were studied. Angiotensin II-induced phosphorylation of ERK1/2, JNK and p38MAPK were assessed by Western blot analysis. c-fos mRNA expression by angiotensin II was determined by reverse transcriptase-polymerase chain reaction in the absence and presence of PD98059, selective inhibitor of ERK1/2-dependent pathways and SB202190, selective p38MAPK inhibitor. Angiotensin II increased phosphorylation of ERK1/2 and p38MAPK, but not JNK. Responses were significantly increased in SHR compared with WKY. Irbesartan, AT1 receptor antagonist, but not PD123319, AT2 receptor blocker, abolished angiotensin II-induced effects. PP2, selective Src inhibitor, decreased angiotensin II-mediated activation of MAP kinases. Angiotensin II increased c-fos mRNA expression in SHR and had a small stimulatory effect in WKY. These actions were inhibited by PD98059, whereas SB202190 had no effect. Angiotensin II-induced activation of vascular ERK1/2 and p38MAPK is increased in SHR. These effects are mediated via AT1 receptors, which activate Src-dependent pathways. Overexpression of c-fos mRNA in SHR is due to ERK1/2-dependent, p38MAPK-independent pathways. Our results suggest that angiotensin II activates numerous MAP kinases in VSMCs and that differential activation of these kinases may be important in altered growth signaling in VSMCs from SHR.Keywords
This publication has 32 references indexed in Scilit:
- Correction of Arterial Structure and Endothelial Dysfunction in Human Essential Hypertension by the Angiotensin Receptor Antagonist LosartanCirculation, 2000
- Contribution of synthetic phenotype on the enhanced angiotensin II-generating system in vascular smooth muscle cells from spontaneously hypertensive ratsJournal Of Hypertension, 1999
- Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteriesJournal Of Hypertension, 1999
- MAP kinases and vascular smooth muscle functionActa Physiologica Scandinavica, 1998
- Molecular and cellular mechanisms of action of angiotensin II (AT1) receptors in vascular smooth muscleJournal of Human Hypertension, 1998
- Growth Factors and Mitogen-Activated Protein KinasesHypertension, 1998
- Angiotensin II responses of vascular smooth muscle cells from hypertensive rats: enhancement at the level of p42 and p44 mitogen activated protein kinaseBritish Journal of Pharmacology, 1997
- Mitogen-activated protein kinase pathwaysCurrent Opinion in Cell Biology, 1997
- Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension.Hypertension, 1994
- Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells.Circulation Research, 1988